Blood pressure goals in type 2 diabetes—assessing the evidence

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 5, 2017, Pages 319-321

  Nilsson, Peter M ^a   Kjeldsen, Sverre E ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; ANTIHYPERTENSIVE AGENT;

ACUTE HEART INFARCTION; AGING; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; COMPLICATION; OBSERVATIONAL STUDY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; OBSERVATIONAL STUDIES AS TOPIC;

EID: 85011396915     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30035-9     Document Type: Note

References (13)

1. 1 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
2. 2 Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
3. 3 Brunström, M, Carlberg, B, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
4. 4 Brunström, M, Eliasson, M, Nilsson, PM, Carlberg, B, Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews. J Hypertens 35 (2017), 453–462.
5. 5 Mancia, G, Fagard, R, Narkiewicz, K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31 (2013), 1281–1357.
6. 6 American Diabetes Association. Standards of medical care in Diabetes—2017. Diabetes Care 40:suppl 1 (2017), S1–S135.
7. 7 Adamsson Eryd, S, Gudbjörnsdottir, S, Manhem, K, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ, 354, 2016, i4070.
8. 8 Adler, AI, Stratton, IM, Neil, HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000), 412–419.
9. 9 SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
10. 10 Kjeldsen, SE, Lund-Johansen, P, Nilsson, PM, Mancia, G, Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 67 (2016), 808–812.
11. 11 Drawz, PE, Pajewski, NM, Bates, JT, et al., for the SPRINT Study Research Group. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study. Hypertension 69 (2017), 42–50.
12. 12 Parati, G, Ochoa, JE, Bilo, G, Zanchetti, A, SPRINT blood pressure: sprinting back to Smirk's basal blood pressure?. Hypertension 69 (2017), 15–19.
13. 13 ACCORD Study Group, Cushman, WC, Evans, GW, Byington, RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.